Sundar S, Murray H W
Kala-Azar Medical Research Center, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
J Infect Dis. 1996 Mar;173(3):762-5. doi: 10.1093/infdis/173.3.762.
Twenty-one Indian patients with visceral leishmaniasis who did not respond to or relapsed after 28-60 days of pentavalent antimony therapy were treated with amphotericin B lipid complex (ABLC). Five infusions (3 mg/kg each) given every second day over 9 days (total dose, 15 mg/kg) resulted in a 100% apparent cure response. In 4 other patients who had not responded to antimony, apparent cure was also induced by ABLC given 3 mg/kg a day 5 consecutive days (total dose, 15 mg/kg). Fever and chills developed routinely during the initial 2-h infusions; these reactions were tolerated and diminished with successive infusions. Six months after treatment, all 25 patients were healthy, had parasite-free bone marrow aspirates, and were considered cured. ABLC is effective short-course therapy for kala-azar patients who do not respond to conventional antimony treatment.
21例对五价锑治疗28 - 60天无反应或复发的内脏利什曼病印度患者接受了两性霉素B脂质复合物（ABLC）治疗。每2天输注5次（每次3mg/kg），持续9天（总剂量15mg/kg），显效率达100%。另外4例对锑无反应的患者，连续5天每天给予3mg/kg的ABLC（总剂量15mg/kg）也诱导了显效。在最初2小时输注期间通常会出现发热和寒战；这些反应可耐受，且随着后续输注而减轻。治疗6个月后，所有25例患者均健康，骨髓穿刺未发现寄生虫，被认为已治愈。ABLC是对传统锑治疗无反应的黑热病患者的有效短程疗法。
